Cyclin A overexpression is associated with chemosensitivity to paclitaxel‑based chemotherapy in patients with esophageal squamous cell carcinoma

Huang,Jun‑Xing; Shen,Shuang‑Le; Lin,Mei; Xiao,Wei; Chen,Wei‑Chang; Lin,Mao‑Song; Yu,Hong; Chen,Ping; Qian,Rong‑Yu

doi:10.3892/ol.2012.814

Cyclin A overexpression is associated with chemosensitivity to paclitaxel‑based chemotherapy in patients with esophageal squamous cell carcinoma

Authors:
- Jun‑Xing Huang
- Shuang‑Le Shen
- Mei Lin
- Wei Xiao
- Wei‑Chang Chen
- Mao‑Song Lin
- Hong Yu
- Ping Chen
- Rong‑Yu Qian
View Affiliations

Affiliations: Department of Oncology, The People's Hospital of Taizhou, Taizhou Medical School, Nantong and Yangzhou University, Taizhou, Jiangsu 225300, P.R. China, Department of Pathology, The People's Hospital of Taizhou, Taizhou Medical School, Nantong and Yangzhou University, Taizhou, Jiangsu 225300, P.R. China, Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: July 20, 2012 https://doi.org/10.3892/ol.2012.814
Pages: 607-611

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the correlation between cyclin A expression and efficacy of paclitaxel‑based chemotherapy in patients with esophageal squamous cell carcinoma (ESCC). The expression of cyclin A was examined in 48 newly diagnosed ESCC patients prior to treatment using the MaxVision immunohistochemistry method. The patients received four cycles of paclitaxel‑based chemotherapy, the short‑term treatment efficacy was evaluated and a 3‑year follow‑up was conducted. The response rate was greater in patients with positive cyclin A expression compared with those with negative expression (54.8 vs. 23.5%; χ2=4.373; P<0.05). Univariate and multivariate Cox analysis revealed that clinicopathological stage, degree of differentiation and expression of cyclin A were independent prognosis factors in patients with ESCC following paclitaxel‑based chemotherapy. ESCC patients with positive cyclin A expression demonstrated an increased sensitivity to paclitaxel‑based chemotherapy, suggesting that cyclin A may be used as a marker to predict the treatment efficacy of paclitaxel in patients with ESCC.

View Figures

View References

1.	PC EnzingerRJ MayerEsophageal cancerN Engl J Med34922412252200310.1056/NEJMra03501014657432
2.	S TakenoT NoguchiY TakahashiS FumotoT ShibataK KawaharaAssessment of clinical outcome in patients with esophageal squamous cell carcinoma using TNM classification score and molecular biological classificationAnn Surg Oncol1414311438200710.1245/s10434-006-9286-3
3.	DH IlsonEsophageal cancer chemotherapy: recent advancesGastrointest Cancer Res285922008
4.	L BedenneP MichelO BouchéChemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102J Clin Oncol2511601168200710.1200/JCO.2005.04.711817401004
5.	JA AbramsDL BuonoJ StraussRB McBrideDL HershmanAI NeugutEsophagectomy compared with chemoradiation for early stage esophageal cancer in the elderlyCancer11549244933200910.1002/cncr.2453619637343
6.	H YamashitaK OkumaY SetoA retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II–III esophageal carcinomaJ Surg Oncol100435441200919653240
7.	H ArigaK NemotoS MiyazakiProspective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagusInt J Radiat Oncol Biol Phys75348356200910.1016/j.ijrobp.2009.02.08619735862
8.	C Cordon-CardoMutations of cell cycle regulators. Biological and clinical implications for human neoplasiaAm J Pathol14754556019957677168
9.	JX HuangW YanZX SongRelationship between proliferative activity of cancer cells and clinicopathological factors in patients with esophageal squamous cell carcinomaWorld J Gastroenterol1129562959200510.3748/wjg.v11.i19.295615902736
10.	JX HuangW XiaoWC ChenRelationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinomaWorld J Gastroenterol1659755981201021157974
11.	JX HuangWC ChenM LinClinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinomaDis Esophagus25121129201210.1111/j.1442-2050.2011.01219.x21762277
12.	J HuangEsophageal cancerManual Medical OncologyY SunYK Shi5th editionThe People’s Medical Publishing HouseBeijing4664692007
13.	Y SunThe clinical experiment of anti-tumor drugsManual Medical OncologyY SunYK Shi5th editionThe People’s Medical Publishing HouseBeijing1611622007
14.	T NozoeD KorenagaM FutatsugiH SaekiT OhgaK SugimachiCyclin A expression in superficial squamous cell carcinoma of the esophagus and coexisting infiltrated lymphocyte follicleCancer Lett188221229200210.1016/S0304-3835(02)00434-212406568
15.	MC WolfM StahlBJ KrauseCurative treatment of oesophageal carcinoma: current options and future developmentsRadiat Oncol655201110.1186/1748-717X-6-5521615894
16.	XD ZhangL ShenJ LiProspective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinomaZhonghua Zhong Liu Za Zhi294744772007(In Chinese).
17.	B StordalR DaveyA systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1Curr Cancer Drug Targets9354365200910.2174/15680090978816659219442054
18.	S NakayamaY TorikoshiT TakahashiPrediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cellsBreast Cancer Res11R12200910.1186/bcr223119239702
19.	T HunterJ PinesCyclins and cancerCell6610711074199110.1016/0092-8674(91)90028-W
20.	M PaganoR PepperkokF VerdeW AnsorgeG DraettaCyclin A is required at two points in the human cell cycleEMBO J1196197119921312467
21.	TJ MitchisonThe proliferation rate paradox in antimitotic chemotherapyMol Biol Cell2316201210.1091/mbc.E10-04-033522210845
22.	I AndroicA KrämerR YanTargeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxolBMC Cancer8391402200810.1186/1471-2407-8-39119113992
23.	P BoströmM SöderströmT PalokangasT VahlbergY CollanO CarpenP HirsimäkiAnalysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factorsBMC Res Notes2140148200919615042
24.	BS YoonYT KimS KimPrognostic value of nuclear DNA quantification and cyclin A expression in epithelial ovarian carcinomaEur J Obstet Gynecol Reprod Biol136110115200810.1016/j.ejogrb.2006.10.00817157431
25.	M FraczekZ WozniakD RamseyT ZatonskiT KrecickiClinicopathologic significance and prognostic role of cyclin E and cyclin A expression in laryngeal epithelial lesionsActa Otolaryngol128329334200810.1080/0001648070148774217917837